The idiotype of the Ig expressed by a B-cell malignancy (Id) can serve as a unique tumor-specific antigen and as a model for cancer vaccine development. In murine models of Id vaccination, formulation of syngeneic Id with carrier proteins or adjuvants induces an anti-idiotypic antibody response. However, inducing a potent cell-mediated response to this weak antigen instead would be highly desirable. In the 38C13 lymphoma model, we observed that low doses of free granulocyte/macrophage colony-stimulating factor (GM-CSF) 10,000 units i.p. or locally s.c. daily for 4 days significantly enhanced protective antitumor immunity induced by s.c. Id-keyhole limpet hemocyanin (KLH) immunization. This effect was critically dependent upon effector CD4+ and CD8+ T cells and was not associated with any increased anti-idiotypic antibody production. Lymphocytes from spleens and draining lymph nodes of mice primed with Id-KLH plus GM-CSF, but not with Id-KLH alone, demonstrated significant proliferation to Id in vitro without any biased production of interferon 'y or interleukin 4 protein or mRNA. As a further demonstration of potency, 50% of mice immunized with Id-KLH plus GM-CSF on the same day as challenge with a large s.c. tumor inoculum remained tumorfree at day 80, compared with 17% for Id-KLH alone, when immunization was combined with cyclophosphamide. Taken together, these results demonstrate that GM-CSF can significantly enhance the immunogenicity of a defined self-antigen and that this effect is mediated exclusively by activating the T-cell arm of the immune response.
The idiotypic determinants of the Igs expressed by B-cell malignancies can serve as unique tumor-specific antigens. Sirisinha and Eisen (1) and Lynch et al. (2) were the first to demonstrate that syngeneic tumor-derived Ig could induce the production of antibodies directed against the MOPC-315 idiotype, as well as induce idiotype-specific resistance to tumor growth. The induction of idiotype-specific immunity by active immunization with tumor-derived Ig has subsequently been demonstrated for a number of myeloma (3) (4) (5) (6) and B-cell lymphoma or leukemia models (7) (8) (9) (10) , usually requiring complete Freund's adjuvant or conjugation to a strongly immunogenic carrier protein. In addition, our pilot studies in human patients with lymphoma and myeloma have demonstrated that idiotype-specific immunologic responses can be induced by immunization with autologous tumor-derived idiotypic Ig (Id), conjugated to keyhole limpet hemocyanin (KLH) (11, 12) . A major obstacle limiting the development of human cancer vaccines is the inherent poor immunogenicity of autologous tumor antigens. Further enhancing the immunogenicity of autologous Id remains an important goal of our studies.
Cytokines may influence both the magnitude and the phenotype of the immune response to protein antigens. They can influence and amplify immune responses by affecting the proliferative capacity and differentiation of lymphoid and antigenpresenting cells. For example, granulocyte/macrophage colonystimulating factor (GM-CSF) has pleiotropic effects, including augmentation of antigen presentation in a variety of cells (13) (14) (15) (16) , major histocompatibility complex (MHC) class II antigen expression on monocytes (17, 18) , increased expression of adhesion molecules on granulocytes and monocytes (19) (20) (21) , and amplification of T-cell proliferation (22) . Some studies of tumor cells engineered with cytokine genes have demonstrated the superiority of paracrine GM-CSF delivery in the induction of systemic antitumor immune responses, including those against poorly immunogenic tumor cell lines (23) .
Tumor resistance produced by Id vaccination in the murine B-cell tumor models above is largely antibody-mediated. This is particularly true of the model system of 38C13, a lymphoma that both secretes and expresses surface Ig. 38C13-derived Id, either alone or administered in complete Freund's adjuvant, is nonimmunogenic in syngeneic mice, whereas immunization with Id conjugated to a carrier protein produces anti-idiotypic antibodies and protection against a minimal tumor challenge, but with little evidence for an effector T-cell response (24) . Using this model, we observed that free GM-CSF had a profound effect on the potency of the protective antitumor response elicited by Id-KLH immunization, and that this effect was mediated exclusively by enhancing T-cell immunity.
MATERIALS-AND METHODS
Mice and Tumor. C3H/HeN MTV-female mice 6 to 12 weeks of age were obtained from the Animal Production Area of the National Cancer Institute-Frederick Cancer Research and Development Center (NCI-FCRDC, Frederick, MD). The carcinogen-induced 38C13 B-cell lymphoma has been described (25) and was a gift from R. Levy (Stanford University, Stanford, CA TTo whom reprint requests should be addressed.
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were passaged in vitro 3 days before use. Injections for each experiment were made from the same suspension of tumor cells.
Vaccine Preparation and Administration. Idiotypic IgM (38C13-Id) was rescued by somatic cell hybridization as described (26) , and 38C13-Id and a control IgM(K) were purified from ascites and coupled to KLH to enhance the humoral anti-idiotypic response; conversely, the significantly increased levels of anti-idiotypic antibody induced by the addition of IL-12 were apparently not protective.
In Vivo Depletion of T-Cell Subsets. We next sought to determine whether effector T cells were required for the enhanced protection observed after combined administration of Id-KLH and GM-CSF. Because of the relative ease of systemic cytokine administration, the i.p. route was used for these experiments. In the experiment shown in Fig. 3 (split into A and B for clarity), mice were immunized with Id-KLH s.c. with or without GM-CSF, 10,000 units i.p. daily for 4 days. Two weeks after immunization, mice in each group were randomly assigned to receive intravenous treatment with depleting mAb specific for CD4+ or CD8+ T cells, or with normal rat IgG every other day for three doses. Three weeks after immunization, all mice, including mice that had been immunized with control IgM-KLH in parallel, were challenged i.p. with a single preparation of tumor. A lower challenge dose of 5 x 103 cells was chosen to maximize potential differences between treated and untreated (normal rat IgG-treated) groups. Among untreated mice, the protective effect of Id-KLH immunization was significantly augmented by the addition of GM-CSF (66% survivors, P = 0.05, compared with Id-KLH alone). While the survival of mice immunized with Id-KLH alone was not significantly affected by the depletion of CD4+ T cells, clearly the enhanced protection associated with the addition of GM-CSF was completely abrogated (P = 0.02, Fig. 3A) . It was also clear that the enhanced protection associated with the addition of GM-CSF was completely abrogated by the depletion of CD8+ T cells (no survivors, P < 0.01, Fig. 3B) (29) . Mice were injected with 104 tumor cells s.c. in one flank and then assigned to one of four treatment groups. Later the same day, mice received either Id-KLH s.c. in the opposite flank, with or without GM-CSF, 10,000 units i.p. daily for 4 days, or GM-CSF or diluent alone according to the same schedule. All four groups received a previously titrated dose of CTX (75 mg/kg), which had been determined not to be curative in control, nonimmunized mice, i.p. on day 10. The representative experiment in Proc. Natl. Acad. Sci. USA 93 (1996) effect was transient in control mice receiving either GM-CSF alone or diluent, and within 5 days thereafter virtually all mice in these two groups relapsed with palpable tumor masses. By comparison, a modest delay in tumor recurrence was observed for both groups vaccinated with Id-KLH. Eventually, almost all of the mice receiving Id-KLH alone relapsed; however, almost 50% of mice receiving Id-KLH plus GM-CSF remained tumor free and were apparently cured. Thus, the ability of GM-CSF to enhance the antitumor effect of Id-KLH vaccination was observed in the pattern of tumor relapses following cytoreduction by chemotherapy. Relapsing tumors resulted in progressive tumor growth and death of the hosts.
Survival data pooled from three separate experiments containing these identically treated groups of mice are shown in Fig. SB . The survival of mice receiving GM-CSF alone was indistinguishable from controls receiving diluent, suggesting the lack of any direct antitumor effect of GM-CSF (median survival time was 34 days for both groups). Immunization with Id-KLH alone was associated with prolonged survival (median survival time, 46 days) and a small number of long-term survivors (17%). The combination of Id-KLH and GM-CSF produced significantly prolonged survival (median survival time, 62 days) and a significant number of long-term survivors (48%, P = 0.025, compared with Id-KLH alone).
DISCUSSION
The induction of cell-mediated immunity directed against weak, autologous tumor antigens is a goal of many experimen- tal cancer vaccine strategies. In particular, it is unclear how important humoral responses are in general tumor immune surveillance. We observed that GM-CSF significantly enhanced the immunogenicity of syngeneic, conjugated tumorderived Id. While these studies could also have been performed with unconjugated Id, against minimal tumor challenge doses to detect incremental differences in protective immunity, we felt that experiments using the most potent immunogen available would be more informative.
Consistent with a genetically modified tumor cell vaccine study (23) , free GM-CSF delivered locally with Id-KLH (both s.c.) resulted in significantly augmented protection against a tumor challenge representing lOOX the minimum lethal dose, compared with the immunogen alone. The argument for paracrine cytokine delivery has been that the administration of systemic doses high enough to achieve immunization effects equivalent to local cytokine production would be too toxic. However, in contrast, GM-CSF administered at relatively low doses systemically (i.p.) was also clearly sufficient to elicit enhanced protective antitumor immunity (Figs. 1, 3, and 5 ). This suggests that local paracrine delivery of cytokine is not an absolute requirement for the phenomenon under study. Furthermore, free GM-CSF failed to enhance the generation of systemic antitumor immunity by a vaccine comprised of B16 melanoma cells plus GM-CSF (30) . However, the high dose of GM-CSF (1 mg) used in this study may have been an important difference from the present study, especially given the trend we observed, that the optimal effect of GM-CSF was associated with the lower dose of cytokine, rather than the higher dose (Fig. 1) . Alternatively, the discordant results between these two models may be attributable to differences in the nature of whole cell and defined protein immunogens. Finally, the effects of GM-CSF may be antigen-dependent, or the susceptibility of the two tumor types to immune effector mechanisms may be different.
The ability of GM-CSF to enhance protective antitumor immunity induced by Id-KLH could be directly attributed to the induction of specific T-cell immunity. In vivo T-cell subset depletion experiments performed during the effector phase clearly demonstrated that both CD4+ and CD8+ T cells were required (Fig. 3) . In contrast, the baseline anti-idiotypic antibody levels elicited by Id-KLH immunization alone were not increased whatsoever by the addition of GM-CSF ( Fig. 2A) . This lack of a primary role for anti-idiotypic antibody clearly distinguishes this effect of free GM-CSF from an idiotype-GM-CSF fusion protein (31) and from a DNA vaccine consisting of mixed plasmids encoding idiotype and GM-CSF (32) , both of which demonstrated only antibody production against idiotype without any apparent cell-mediated immunity. The possibility that a minimum threshold level of anti-idiotypic antibody, in addition to CD4+ and CD8+ effector T cells, is required for the enhancing effect of free GM-CSF on tumor protection cannot be formally excluded. However, in our immunized, T-cell depleted mice anti-idiotypic antibody levels remained unaltered (data not shown). In vitro, T-cell proliferative responses from splenocytes and draining lymph nodes were observed against idiotype after priming with the combination of Id-KLH and GM-CSF, but not with Id-KLH alone (Fig. 4) . Consistent with the lack of reported influence of GM-CSF on -the Thl and Th2 dichotomy, the addition of GM-CSF to Id-KLH priming had no effect on cytokine profiles (protein or mRNA) of the response to idiotype.
The critical importance of inducing an idiotype-specific T-cell response is underscored by the case of secreting B-cell tumors, in which any anti-idiotypic antibody response would be expected to be neutralized by the excess of circulating antigen. Evidence suggesting that T cells recognize idiotypic determinants that have been processed and presented as peptides in combination with MHC molecules, rather than as soluble idiotype, has been provided by the isolation of T-cell clones specific for a peptide comprising amino acids 91-101 of the A light chain of MOPC-315, bound to an MHC class II molecule (33) . Furthermore, mice transgenic for this T-cell receptor were able to reject tumors secreting the MOPC-315 myeloma protein (34) . Finally, our characterization of a human, donorderived myeloma idiotype-specific CD4+ T-cell line recovered from a marrow transplant recipient with circulating paraprotein demonstrated blocking of proliferation by anti-MHC class II antibodies, suggesting recognition of an idiotypic peptide bound to MHC molecules on antigen presenting cells (12) .
The precise cellular interactions initiated by GM-CSF delivered with tumor vaccines also remain to be elucidated at the level of antigen processing and presentation, including the possible recruitment of professional antigen presenting cells (35, 36) . Nevertheless, an antitumor effect against a large s.c. inoculum of tumor cells was observed when Id-KLH and GM-CSF were administered in combination (48% tumor-free, compared with 17% for Id-KLH alone; Fig. 5 
